NDAORALCAPSULEPriority Review
Approved
Feb 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
CELONTIN (methsuximide) by Pfizer is clinical pharmacology methsuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. First approved in 1957.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CELONTIN (methsuximide) is an oral anti-epileptic agent approved in 1957 that suppresses the characteristic 3 Hz spike-and-wave activity associated with absence (petit mal) seizures. It works by depressing motor cortex activity and elevating the seizure threshold in the central nervous system. The drug is formulated as an oral capsule for chronic seizure management.
$0.696MPart D
LOE ApproachingDeclining
Small commercial footprint with minimal claims volume signals limited career growth; core team focus is likely on compliance and niche patient retention rather than expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Methsuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and…
Pharmacologic Class:
Anti-epileptic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CELONTIN represents a legacy product with minimal career momentum; opportunities are limited to niche maintenance roles rather than high-visibility growth assignments. Professionals assigned here should expect portfolio responsibility across multiple products or transition planning activities.
Medical Science Liaison
Worked on CELONTIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.